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Abstract
Background: Adenosine-to-inosine (A-to-I) editing of dsRNA by ADAR proteins is a pervasive epitranscriptome
feature. Tens of thousands of A-to-I editing events are defined in the mouse, yet the functional impact of most is
unknown. Editing causing protein recoding is the essential function of ADAR2, but an essential role for recoding by
ADAR1 has not been demonstrated. ADAR1 has been proposed to have editing-dependent and editing-independent
functions. The relative contribution of these in vivo has not been clearly defined. A critical function of ADAR1 is editing
of endogenous RNA to prevent activation of the dsRNA sensor MDA5 (Ifih1). Outside of this, how ADAR1 editing
contributes to normal development and homeostasis is uncertain.
Results: We describe the consequences of ADAR1 editing deficiency on murine homeostasis. Adar1E861A/E861AIfih1-/-
mice are strikingly normal, including their lifespan. There is a mild, non-pathogenic innate immune activation
signature in the Adar1E861A/E861AIfih1-/- mice. Assessing A-to-I editing across adult tissues demonstrates that outside
of the brain, ADAR1 performs the majority of editing and that ADAR2 cannot compensate in its absence. Direct
comparison of the Adar1-/- and Adar1E861A/E861A alleles demonstrates a high degree of concordance on both Ifih1+/+
and Ifih1-/- backgrounds, suggesting no substantial contribution from ADAR1 editing-independent functions.
Conclusions: These analyses demonstrate that the lifetime absence of ADAR1-editing is well tolerated in the
absence of MDA5. We conclude that protein recoding arising from ADAR1-mediated editing is not essential for
organismal homeostasis. Additionally, the phenotypes associated with loss of ADAR1 are the result of RNA editing
and MDA5-dependent functions.
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Background
It is now established that direct RNA modifications,
collectively referred to as the epitranscriptome, are wide-
spread, evolutionarily conserved, and contribute signifi-
cantly to the complexity of gene regulation [1, 2]. A
highly prevalent modification is the deamination of
adenosine to inosine (A-to-I editing) in double-stranded
RNA (dsRNA). A-to-I editing is catalyzed by adenosine
deaminase acting on RNA (ADAR) proteins. It is
estimated that there are over 100 million potential A-to-I
editing sites in humans and tens of thousands in mice
[3, 4], with the majority residing within repetitive se-
quences, such as short interspersed nuclear elements
(SINEs), Alus (primates only), and long tandem repeats
(LTRs) [5]. Depending on the sequence context—coding
sequence, intronic region, untranslated regions, non-
coding RNAs—editing can have varying consequences
for gene expression [6]. Outside of a small number of
examples, the cellular and organismal consequences of
A-to-I editing are relatively poorly understood.
Mammals have three ADARs: ADAR (ADAR1),
ADARB1 (ADAR2), and ADARB2 (ADAR3); although
only ADAR1 and ADAR2 have editing activity in vitro.
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Physiologically, ADAR2 is essential for the specific edit-
ing of a single adenosine in the coding sequence of the
glutamate receptor 2 subunit (Gria2) transcript, termed
the Q/R site, encoding a neurotransmitter receptor in
the brain [7–9]. Inosine is interpreted as guanine by the
ribosome so editing of the Gria2 mRNA recodes a geno-
mically encoded glutamine (Q) to arginine (R), varying
the permeability of the pore. Adarb1-/- (Adar2-/-) mice
cannot edit the Q/R site adenosine, leading to seizures
and early lethality. Despite thousands of other editing
events identified in both coding and non-coding regions,
genomic substitution of the single A to G at the Q/R
site rescued the Adar2-/- phenotype [7, 10]. This result
defined the paradigm that RNA editing is a means to
post-transcriptionally modify coding sequences and “re-
code” DNA sequences. Unlike ADAR2, the role of
ADAR1 has proven more complex.
ADAR1 is expressed throughout the body, unlike
ADAR2 which is highest in the brain [11]. There are two
isoforms of ADAR1: a constitutively expressed ADAR1
p110, which is primarily nuclear-restricted, and a longer
interferon (IFN) inducible ADAR1 p150, which localizes
to both nucleus and cytoplasm [12]. Adar-/- (Adar1-/-)
mice died at embryonic day 11.5–12.0 (E11.5–12.0) with
a profound upregulation of type I IFN and IFN-
stimulated genes (ISGs) [13–15]. Likewise, adult somatic
deletion of Adar1 resulted in innate immune activation
and cell death [14, 16–19]. Mice homozygous for a sin-
gle amino acid substitution resulting in an editing-
deficient ADAR1 protein (Adar1E861A/E861A) die at
E13.5, with remarkably similar phenotypes to the null
allele [19]. Activation of the innate immune sensing
system, termed an interferonopathy, is observed in the
subset of Aicardi-Goutières syndrome (AGS) patients
who harbor mutations in ADAR, demonstrating that
the transcriptional response to loss of ADAR1 activity
is conserved across mammals [17, 20–22].
In mice and humans, most editing occurs in repetitive
sequences capable of base-pairing to form intramolecular
dsRNA structures [23–25]. Using murine genetics, we and
others demonstrated that editing of endogenous RNA is
a critical function of ADAR1, acting to prevent sensing
of endogenous (self ) dsRNA as foreign [17, 19, 26, 27].
A central function of the innate immune system is the
recognition of foreign (non-self ) dsRNA by pattern
recognition receptors (PRRs) in the cytoplasm. Upon de-
tecting long dsRNA, the PRR melanoma differentiation-
associated gene 5 (MDA5, gene name Ifih1) oligomerizes
to form a filament leading to activation of mitochondrial
antiviral signaling (MAVS), resulting in the production
of type I IFN and the propagation of downstream de-
fence signals [28, 29]. Concurrent deletion of MDA5 or
MAVS with ADAR1 extended the survival of Adar1-/-
animals until shortly after birth [17, 26]. Viability of the
ADAR1 editing-deficient mice was also rescued by dele-
tion of MDA5. These findings suggested that RNA editing
is the key function of ADAR1 during early development
to prevent activation of MDA5 by endogenous dsRNA.
Editing-dependent and editing-independent functions
of ADAR1 have been proposed, including involvement
in multiple aspects of microRNA (miRNA) biogenesis
[30–35], messenger RNA (mRNA) stability [36, 37], alter-
nate 3’-UTR usage [33], splicing [38, 39] and translation
[40]. Analysis of the Adar1-/-Mavs-/- and Adar1p150-/-
Mavs-/- rescued mice identified phenotypes associated
with the loss of ADAR1 that were considered independent
of MAVS/MDA5, including developmental defects in
the kidney, small intestine, lymph node, and a failure of
B lymphopoiesis [17]. It is unclear if these phenotypes
reflect editing-dependent or editing-independent func-
tions of ADAR1.
Due to embryonic lethality of the Adar1-/- and
Adar1E861A/E861A mice, establishing the in vivo rele-
vance of ADAR1’s functions to adult homeostasis had
not been possible. In contrast to the Adar1-/-Ifih1-/- or
Adar1-/-Mavs-/- that die within days of birth, the
Adar1E861A/E861AIfih1-/- survived until at least four
weeks of age [19]. We have assessed the requirement
for ADAR1 activity during adult murine homeostasis
using these rescued ADAR1 editing-deficient animals.
We directly compared the Adar1-/- and Adar1E861A al-
leles, on both a Ifih1+/+ and Ifih1-/- background, on the
day of birth and in an acute adult somatic mutation
model to evaluate editing-independent functions of
ADAR1. We conclude that the core function of ADAR1-
mediated editing is to prevent the formation of MDA5
substrates and that other effects of ADAR1-mediated
editing, such as protein recoding and on miRNA biology,
are not essential for murine homeostasis in vivo.
Results
Adar1E861A/E861AIfih1-/- animals have a normal lifespan
and low weaning weight
The Adar1E861A/E861AIfih1-/- are viable [19]. The most ap-
parent phenotype of the Adar1E861A/E861AIfih1-/- animals
was reduced weaning weight, with Adar1E861A/E861AIfih1-/-
animals ~ 30% lighter than the controls (day 20–21 post
birth; Fig. 1a). By 12 weeks, the Adar1E861A/E861AIfih1-/-
females had a normal body weight compared to both
wild-type (WT) C57BL/6 and Adar1+/+Ifih1-/- animals
(Fig. 1b, Additional files 1 and 2: Video S1, S2). Males
remained lighter at 12 weeks, although the difference
was less than at weaning, being ~ 9% and ~ 17% lighter
than C57BL/6 or Adar1+/+Ifih1-/-, respectively (Fig. 1c,
Additional files 1 and 2: Video S1, S2). Adar1E861A/+
Ifih1-/- animals had normal body weight. There was
no significant difference in the long-term survival of
the Adar1E861A/E861AIfih1-/- animals compared to
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Adar1E861A/+Ifih1-/- animals, surviving to > 80 weeks of
age (Fig. 1c). The oldest Adar1E861A/E861AIfih1-/- animals
have survived to > 115 weeks of age (>805 days). The
median life expectancy of C57BL/6 mice is in the range
of 676–878 days [41, 42]. Both male and female
Adar1E861A/E861AIfih1-/- animals are fertile, which for the
males, at least, this is consistent with the primary role
reported for ADAR2 in editing in the testis [43].
Mild innate immune activation in the absence of MDA5
To determine if there was activation of innate immune
sensing in the Adar1E861A/E861AIfih1-/- animals, as seen
in the Adar1-/- [14] and the Adar1E861A/E861A [19], the
expression of four ISGs was assessed across a range of
tissues (Fig. 2a). The expression of these ISGs increased
dramatically upon deletion/mutation of ADAR1 in both
human and mouse [17, 21]. There was either no change
or a subtle increase in ISGs in the tissues assessed (up to
tenfold over C57BL/6 s). In whole brain, three of four
ISGs were significantly increased. By comparison, in E12.5
Adar1E861A/E861A vs. Adar1+/+ fetal brain, these same ISGs
were upregulated between ~ 125 and ~ 550-fold (Fig. 2a).
Therefore, MDA5 is the primary conduit of innate im-
mune signal activation in ADAR1 editing-deficient mice.
However, a well-tolerated and, apparently non-pathogenic,
low-level, innate immune activation occurs in the absence
of MDA5 via currently unknown mechanisms.
The protein levels of eight cytokines/chemokines in
peripheral blood (PB) serum that increased upon som-
atic deletion of Adar1 were assessed [17]. There was no
increase in any of the proteins assessed including IFNβ,
IFNγ, CCL2, and CXCL10 (Fig. 2b). The only difference
was an Ifih1-/- genotype-dependent reduction in the ex-
pression of CCL11 (Fig. 2b). As a positive control, the
expression of these proteins was assessed in supernatant
from cultures of immortalized hematopoietic cells [44],
generated from R26-CreERT2 Adar1E861A/fl bone marrow
(BM) cells, treated with tamoxifen in vitro (Fig. 2b).
Despite the increased ISG mRNAs there is no resultant
increase in circulating protein levels.
Normal hematopoiesis in the absence of ADAR1-mediated
A-to-I editing
Hematopoietic cells have a profound dependence on
ADAR1 [13, 14, 16, 18, 19, 45]. We assessed
hematopoiesis in 12-week-old Adar1E861A/E861AIfih1-/-
animals and three control populations: age-/sex-matched
C57BL/6 animals bred and housed in the same facility;
Adar1+/+Ifih1-/- animals; and Adar1E861A/+Ifih1-/- animals.
PB indices in Adar1E861A/E861AIfih1-/- animals were com-
parable to C57BL/6 mice (Fig. 3a). For reasons presently
unknown, the total PB leukocyte counts were lower in the
Adar1+/+Ifih1-/- cohort compared to the other genotypes
(Fig. 3a, b). There were several statistically significant
differences between the Adar1E861A/E861AIfih1-/- animals
and C57BL/6 animals including a reduction in the per-
centage, but not numbers, of granulocytes and an in-
crease in the number, but not percentage, of B cells in
the PB (Fig. 3b). All Ifih1-/- animals, irrespective of
Adar1 status, presented with a mild anemia compared
to the C57BL/6 cohorts (Fig. 3c, d). Platelet numbers
were normal in all genotypes (Fig. 3e).
Within the BM, relatively mild and subtle changes
were apparent that reflected the PB. Total BM cellularity
and myeloid development was essentially normal be-
tween genotypes (Fig. 3f, g). Analysis of B-cell differenti-
ation demonstrated that the lower B-cell numbers in the
Adar1+/+Ifih1-/- stemmed from a reduction of cells at
the ProB cell stage (Fig. 3h). Consistent with the Ifih1-/--
dependent anemia, there were reduced numbers of ma-
ture CD71-Ter119+ erythroid cells in the BM of animals
with this genotype (Fig. 3i). In the stem and primitive
progenitor populations, there were relatively subtle dif-
ferences among the groups, but in all cases the numbers
c
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Fig. 1 Reduced weaning weight and normal survival of Adar1E861A/E861AIfih1-/- animals. a Weaning weight of indicated genotypes. b Weight of 12-
week-old male and female animals of indicated genotypes. c Kaplan–Meier survival plot of Adar1E861A/+Ifih1-/- and Adar1E861A/E861AIfih1-/-. Number
of animals at risk indicates the number in the cohort/age bracket. Results are mean ± SEM with *P < 0.05, **P < 0.005, and ****P < 0.00001
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of each population were largely normal (Fig. 3j, k).
Hematopoiesis in the spleen (Fig. 3l) and thymus
(Fig. 3m) was normal compared to controls. ADAR1-
mediated editing in not required for homeostatic
hematopoiesis once MDA5 is inactivated.
Normal tissue development in the absence of
ADAR1-mediated A-to-I editing
Tissues from 12-week-old Adar1E861A/E861AIfih1-/- and
age-/sex-matched Adar1E861A/+Ifih1-/- littermates were
subjected to a genotype blinded histological assessment by
a
b
Fig. 2 Modest activation of ISG expression in Adar1E861A/E861AIfih1-/- tissues. a Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) of four ISGs from tissues of 12-week-old mice, with the exception of the first panel comparing 12-week-old brain with E12.5 fetal
brain from Adar1E861A/E861AIfih1+/+ embryos. Data represent mean ± SEM (n = 3/genotype); all samples normalized to C57BL/6. b PB serum cytokine
levels from indicated genotypes. Positive control = supernatant from tamoxifen treated R26-CreERT2 Adar1E861A/fl hematopoietic cell line. Results
are mean ± SEM; significance determined using two-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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an independent core service facility. No significant path-
ology or differences were observed across the > 20 tissues
and structures assessed between Adar1E861A/E861AIfih1-/-
to Adar1E861A/+Ifih1-/- littermates. The kidney, spleen, and
small intestine were normal (Fig. 4a). All other organs
assessed, including brain, were histologically normal
(see Additional file 3: Dataset S1).
Due to the reduced weaning weight and requirement
for ADAR1 in bone/osteoblast homeostasis [46], we
quantitated the bone parameters in 12-week-old
Adar1E861A/E861AIfih1-/- animals compared to controls by
microCT [47]. Both male and female mice were assessed;
however, due to variability in bone indices with estrus in
females, we focused our analysis on the males (female
data in Additional file 3: Figure S1). The total tibial
length and trabecular bone parameters were normal in
the Adar1E861A/E861AIfih1-/- animals (Fig. 4b–g). The only
significant differences were modest changes in the cortical
thickness (Fig. 4h, i) and cortical area (Fig. 4j) between
the Adar1E861A/E861AIfih1-/- animals and the C57BL/6
and Adar1+/+Ifih1-/- animals. There was a reduced endo-
cortical perimeter when the Adar1E861A/E861AIfih1-/-
were compared to the Adar1+/+Ifih1-/- animals (Fig. 4k),
but not to the C57BL/6 s. Therefore, ADAR1-mediated
A-to-I editing is dispensable for normal organ and skel-
etal development once MDA5 is inactivated.
Transcriptome analysis of whole brain from adult
rescued mice
ADAR1 loss-of-function mutations in humans are one of
the causes of AGS [17, 20, 21]. AGS is characterized by
severe changes in the brain and neurological function,
so we sought to understand how a loss of editing by
ADAR1 impacted the brain transcriptome. Whole brains of
12-week-old Adar1E861A/E861AIfih1-/- and Adar1+/+Ifih1-/-
male mice were assessed (Fig. 5a, Additional file 4:
Dataset S2). Compared to that previously observed in
the Adar1-/- and Adar1E861A/E861A fetal tissues where the
expression of many hundreds of transcripts is altered
[14, 19], there were surprisingly limited changes in the
transcriptome of the Adar1E861A/E861AIfih1-/- brain.
Twenty-nine genes were significantly different between
the genotypes (log2FC ≥ 1, ≥ 2 counts per million [CPM]
in all three replicates/genotype). Most changes (n = 24)
were transcripts upregulated in the absence of editing
(Fig. 5b). Pathway analysis confirmed the modest innate
immune activation signature, as observed with quantita-
tive polymerase chain reaction (qPCR), with GO path-
ways relating to IFN response and viral defence the only
pathways enriched in the differentially expressed genes
(Fig. 5c; Additional file 4: Dataset S2). Quantitative set
analysis for gene expression (QuSAGE) was performed
to examine the transcriptional signature of ADAR1-
editing deficiency, defined in our previous analysis of the
Adar1E861A/E861A fetal liver [19], in the adult brains
(Fig. 5d). To do this, differentially expressed genes in the
E12.5 Adar1E861A/E861A fetal liver were used to create a
gene set and the expression of the genes in this set were
assessed in both the adult brain of Adar1E861A/E861AIfih1-/-
(vs. Adar1+/+Ifih1-/-) and, as a comparator, the E12.5
fetal brain of Adar1E861A/E861A embryos (vs. Adar1+/+;
Fig. 5d, Additional file 4: Dataset S2). The ADAR1-
editing deficient signature is enriched in the adult brain
even in the absence of MDA5, however, at a greatly re-
duced level compared to the MDA5 WT Adar1E861A/E861A
E12.5 fetal brain.
ADAR1 is the primary editing enzyme in peripheral tissue
and editing levels are significantly reduced in the
Adar1E861A/E861AIfih1-/- tissues
One potential explanation for the normality of the res-
cued animals could be redundancy for editing targets
with ADAR2. We therefore assessed eight tissues for the
expression of Adar isoforms and editing of known sites:
BM, spleen, thymus, liver, brain, kidney, small intestine,
and heart. Adar1 transcript could be detected in all tis-
sues, whereas Adar2 transcript was expressed only in
brain, kidney, and liver with low levels in spleen and BM
(Fig. 6a–h, upper panels). Adar3 transcript was detected
in brain and at low levels in the liver only. Modestly
increased overall expression of Adar1 was observed in
Adar1E861A/E861AIfih1-/- relative to Adar1+/+Ifih1-/- in
BM, spleen, thymus, liver, kidney, and heart, possibly
reflecting the mild ISG activation observed (Fig. 4a).
(See figure on previous page.)
Fig. 3 Hematopoiesis and B-cell production are normal in the absence of ADAR1 editing. PB, BM, spleen, and thymus analyzed of 12-week-old
mice. a–e PB analysis from C57BL/6 (n = 25), Adar1+/+Ifih1-/- (n = 15), Adar1E861A/+Ifih1-/- (n = 17), Adar1E861A/E861AIfih1-/- (n = 19) indicating (a) total
leukocyte counts, (b) % and absolute number of each leukocyte subtype, (c) red blood cell counts, (d) hemoglobin levels, and (e) platelet
numbers. f–j BM analysis of C57BL/6 (n = 5), Adar1+/+Ifih1-/- (n = 10), Adar1E861A/+Ifih1-/- (n = 11), Adar1E861A/E861AIfih1-/- (n = 11) showing (f)
total leukocyte counts per femur, (g) numbers of granulocytes and monocytes, (h) mature (B220 + IgM+) and immature (B220 + IgM-) B-cell
populations and subsets of the immature populations as indicated, (i) erythroid cells; and j–k hematopoietic stem and progenitor popula-
tions using two methods. (l) Spleen weight and cellularity, B cells and granulocyte numbers per spleen from C57BL/6 (n = 6), Adar1+/+Ifih1-/-
(n = 12), Adar1E861A/+Ifih1-/- (n = 12), Adar1E861A/E861AIfih1-/- (n = 14). (m) Thymic cellularity and CD4/CD8 composition in C57BL/6 (n = 6), Adar1+/+Ifih1-/-
(n = 12), Adar1E861A/+Ifih1-/- (n = 12), Adar1E861A/E861AIfih1-/- (n = 13). Results are mean ± SEM; data shown are pooled from at least three
independent experiments; significance determined using two-way ANOVA with correction for multiple comparisons; *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001
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(See figure on previous page.)
Fig. 4 Normal organ histology in the absence of ADAR1 RNA editing. a Hematoxylin and eosin (H&E)-stained sections of the indicated organs of
Adar1E861A/E861AIfih1-/- (n = 4; 2 male, 2 female) and Adar1E861A/+Ifih1-/- (n = 4; 2 male, 2 female) control littermates. 10× magnification with 100-μM scale
bar; 40× inset for each. b–g MicroCT analysis of tibial bone; C57BL/6 (n = 4), Adar1+/+Ifih1-/- (n = 4), Adar1E861A/+Ifih1-/- (n = 7), Adar1E861A/E861AIfih1-/-
(n = 9). b Representative images of reconstructed trabecular region of the secondary spongiosa within the proximal tibia with color-coded quantitative
mineralization from indicated genotypes. c Tibial length, (d) Trabecular bone volume, (e) trabecular number, (f) trabecular separation, and (g) trabecular
thickness. h–k MicroCT analysis of cortical bone of the same samples used for panels (b–g). h Representative images of reconstructed cortical bone
with color-coded quantitative mineralization, (i) cortical thickness, (j) cortical bone area, and (k) endocortical perimeter. Results are mean ± SEM;
significance tested using ANOVA, *P < 0.05, **P < 0.01
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A-to-I editing across a range of defined substrates was
assessed using microfluidics multiplexed PCR and deep
sequencing (mmPCRseq) [48], allowing accurate mea-
surements of editing of up to 11,103 sites in 557 loci
(Fig. 6a–h, lower panels, Additional file 5: Dataset S3).
Changes in editing across the tissues principally reflected
the expression profile of Adar1 and Adar2. In the brain,
where there are higher relative levels of Adar2 than
Adar1, there is a largely preserved editome with evi-
dence for a subset of ADAR1-specific and ADAR2-
specific events (dots on y-axis or x-axis, respectively),
but the majority can be edited by both. In contrast, in
hematopoietic tissues there is little/no detectable Adar2
and with this there is a near complete absence of editing
of known sites when ADAR1 editing is inactivated. In
other peripheral tissues assessed, Adar1 predominates
and most editing of known sites was lost in the
Adar1E861A/E861A-derived samples. Examples for
ADAR1-specific, ADAR2-specific, and ADAR1/2 shared
editing sites were observed (Fig. 6i). We further
assessed the status of evolutionary conserved recoding
events across the tissues [49]. The most informative tis-
sue was the brain, where the majority of these tran-
scripts were robustly expressed (Fig. 6j). In the brain,
editing at most sites was preserved indicating that
ADAR2 was editing these sites. Known ADAR1
dependent sites such as Bclap and two sites in the
Htr2c transcript had significantly reduced/no editing in
the brain [13, 50]. For the remaining tissues, there were
several patterns apparent: the transcripts were not de-
tected as expressed in the tissue assessed (indicated in
white; see Additional file 5: Dataset S3 for mouse EN-
CODE expression data from tissues for each transcript);
that editing of the conserved sites was preserved indi-
cating an ADAR2-specific target, even in tissue with
relatively low levels of Adar2 as assessed by qPCR (see
Cog3 as an example); that there was a loss of editing at
these sites in the Adar1E861A/E861AIfih1-/--derived tissues
indicating these sites are ADAR1-dependent (see Kcna1
in the liver, Nova1 in the bone marrow, Cyfip2 in the
liver and small intestine for examples). The failure to
edit the conserved sites in the Adar1E861A/E861AIfih1-/-
tissues suggests that while they are ADAR1-dependent
sites, their absence was not deleterious. This analysis
demonstrated that editing in the tissues outside the cen-
tral nervous system that were assessed is primarily medi-
ated by ADAR1, yet despite the loss of this editing, these
tissues are normal in the absence of MDA5.
The absence of ADAR1 or loss of ADAR1-mediated A-to-I
editing are equivalent in vivo
A direct comparison of the specific loss of ADAR1-
mediated editing and complete absence of ADAR1 pro-
tein would clarify the potential for ADAR1 to contribute
to processes beyond A-to-I editing. The difference in
viability and tissue phenotypes between Adar1-/-Ifih1-/-
and Adar1E861A/E861AIfih1-/- rescued mice suggested
there may be editing-independent roles of ADAR1. We
initially assessed cohorts of Adar1-/-Ifih1-/- and
Adar1E861A/E861AIfih1-/- pups and littermate controls at
the day of birth, a time point when the majority of the
Adar1-/-Ifih1-/- are viable [17]. At this developmental
age, there was no difference between the ADAR1 null
and editing-deficient alleles with the frequency of B cells
in the spleen being equivalent and no apparent activation
of the innate immune sensing pathway (Fig. 7a, b).
Next, we evaluated this using an acute somatic dele-
tion model comparing R26-CreER Adar1fl/+ (control; ex-
pressing WT ADAR1 protein after tamoxifen treatment),
R26-CreER Adar1fl/fl (ADAR1 protein null after tamoxi-
fen treatment), and R26-CreER Adar1fl/E861A (expressing
an editing deficient ADAR1 protein after tamoxifen
treatment) on both an MDA5 WT and null background
(Fig. 7c). All mice were aged at least eight weeks at the
initiation of up to 28 days treatment with tamoxifen ad-
ministered via the food (400 mg/kg in standard chow).
The R26-CreER Adar1fl/fl and R26-CreER Adar1fl/E861A
animals both lost condition and weight from day 14 on-
ward (Fig. 7d–f ). This decline in health was accompanied
by a severe reduction in PB indices and the euthanasia of
all R26-CreER Adar1fl/E861A animals and three of four
R26-CreER Adar1fl/fl animals prior to day 28 of treatment
(Fig. 7f, g). All remaining genotypes remained healthy at
day 28 and were assessed on day 29 (Fig. 7d). Upon eu-
thanasia or cessation of tamoxifen as indicated, genotyp-
ing confirmed the efficient recombination of the floxed
(See figure on previous page.)
Fig. 6 ADAR1 is the predominant ADAR in peripheral tissues and affects editing levels across all tissues. a–h Upper panels: qRT-PCR of Adar
expression from tissues of 12-week-old mice. Data normalized to Ppia and are the mean ± SEM (n = 3/genotype). n.d not detected. Lower panels:
Editing of known sites measured using multiplexed PCR and deep sequencing (mmPCR-seq) in each tissue. Editing levels in Adar1+/+Ifih1-/-
(ADAR1 WT; y-axis) plotted against those in the Adar1E861A/E861AIfih1-/- (ADAR1 editing deficient; x-axis) with each individual site indicated by a
dot. Gray dot = no significant difference, red dot = P < 0.05. i Examples of editing at three loci. Colored panels indicate the edited nucleotides
((+) strand: green = A, orange = G; (-) strand: red = T(A), blue = C(G)). Bri3bp is a representative shared Adar1 and Adar2 target at the third adenosine;
Trim12c is representative of an ADAR1-specific target. Htr2c is representative of an ADAR1-specific recoding event at the first two sites. Percent
editing is indicated for each site. j Analysis of conserved editing sites in each tissue by mmPCR-seq. Editing sites were compared between
Adar1+/+Ifih1-/- (ADAR1 WT) and Adar1E861A/E861AIfih1-/- tissues as indicated. White indicates no expression/reads detected in the tissue. Data
include all sites with > 100 reads in the mmPCR-seq
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allele in the R26-CreER Adar1fl/+ animals (Fig. 7e). The
R26-CreER Adar1fl/fl and R26-CreER Adar1fl/E861A, while
both moribund and requiring euthanasia, retained the
floxed allele indicative of selection against deletion as pre-
viously observed in other settings [14, 18, 19]. Strikingly,
the absence of MDA5 allowed the efficient recombination
of the floxed allele in both the R26-CreER Adar1fl/flIfih1-/-
and R26-CreER Adar1fl/E861AIfih1-/- animals (Fig. 7e).
We focused our assessment on hematopoiesis, given
the well-characterized impact of ADAR1 deficiency on
this system. Across PB (Fig. 7g), BM (Fig. 7h–m), spleen
(Fig. 7n, Additional file 3: Figure S2), and thymus
(Fig. 7o, Additional file 3: Figure S2), the results were
highly comparable: that the complete absence of ADAR1
protein and the specific absence of A-to-I editing by
ADAR1 were largely indistinguishable, and that the dele-
tion of MDA5 rescued both the ADAR1 null and editing
deficient alleles equivalently. In the presence of MDA5,
the deletion of ADAR1 or prevention of editing by
ADAR1 resulted in a loss of erythroid progenitors
(Fig. 7j), a block in B-cell maturation in the BM (Fig. 7k),
an accumulation of phenotypic stem and primitive pro-
genitor populations (Fig. 7l) with a loss of the committed
myelo-erythroid progenitor populations (Fig. 7m). These
changes were prevented by the deletion of MDA5. The
activation status of the innate immune response was
queried using expression of Sca1, a cell surface protein
induced by IFN resultant from an innate immune
response [14, 51]. In the R26-CreER Adar1fl/fl and
R26-CreER Adar1fl/E861A BM primitive hematopoietic
population, there was a profound upregulation of Sca1
expression that was completely prevented by deletion
of MDA5 (Fig. 7p). Intestinal length was assessed as
prior work identified intestinal shortening following
the somatic deletion of Adar1 in a Mavs-/- background,
although the age of these animals was not provided
[17]. No difference in intestinal length was observed in
our cohorts (Fig. 7q). These results demonstrate that
the complete absence of ADAR1 and the specific
absence of ADAR1-mediated A-to-I editing, in either
the presence or absence of MDA5, respectively, are
largely indistinguishable in adult mice. Therefore, pre-
venting MDA5 substrate formation requires A-to-I
editing of endogenous RNA and is the primary in vivo
function of ADAR1.
Discussion
The consequences of altered ADAR1 function are se-
vere, from embryonic lethality in mice to debilitating
neurological disease and systemic interferonopathy in
humans with loss-of-function alleles [22, 52], to putative
oncogenic roles when overexpressed [31, 53, 54], so it is
critical to clearly define the key function(s) of ADAR1.
In contrast to the physiologically essential role of tran-
script recoding by ADAR2, the importance of recoding
to the biology of ADAR1 was unknown. In addition to
protein recoding, ADAR1 can edit dsRNA substrates
resulting in changes in multiple aspects of miRNA bio-
genesis or function, affect mRNA stability, 3’-UTR
length and translation, and modify splice site usage in
addition to altering dsRNA secondary structures, which
have been proposed to interface with the innate immune
sensing system [19, 55]. We now demonstrate that the
absence of ADAR1-mediated editing is surprisingly well
tolerated, once the innate immune sensor MDA5 is de-
leted. Adar1E861A/E861AIfih1-/- mice are strikingly normal
in a homeostatic state. Given the extent of A-to-I editing
in the transcriptome, the precedent of ADAR2/Gria2
and the diverse functions in which ADAR1 is implicated
[2, 6, 56, 57], this was unexpected. This demonstrates
that exonic recoding of transcripts by ADAR1, as well as
other proposed editing-dependent effects of ADAR1 on
gene expression, are not essential for development and
adult homeostasis. Consistent with this, we saw very few
changes to the global gene expression profile in adult
brain of Adar1E861A/E861AIfih1-/- mice. The lack of phe-
notypes in the Adar1E861A/E861AIfih1-/- mice at homeo-
stasis reveals that ADAR1’s primary and physiologically
(See figure on previous page.)
Fig. 7 The complete absence of ADAR1 and the specific loss of ADAR1-mediated editing activity phenocopy. a Percentage of B cells (B220 + ve)
spleen leukocytes in the indicated genotypes at the day of birth, n as indicated in (a). Data are pooled from at least two separate litters per genotype.
b Expression of Ifi44, Ifit1, and Irf7 transcript in whole brain from the indicated genotypes on the day of birth, n as for (a). c Experimental outline of
somatic deletion model; all mice were aged ≥ 8 weeks at tamoxifen initiation (defined as day 0). d Kaplan–Meier survival plot of each genotype.
All Ifih1-/- lines fall under the Adar1fl/+. Mice were analyzed on the day of euthanasia or day 29 as indicated. e Genotyping of genomic DNA at day
0 (PB-derived cells) and day 28/euthanasia (BM-derived cells) for each genotype. f Change in body weight (day 0 normalized to 100%) and day
28/euthanasia. g PB leukocyte counts and lineage distribution within the total leukocyte count at day 0 (pre-tamoxifen) and day of euthanasia or
day 28 as indicated in (b). Statistics compare day 0 and day of euthanasia/day 28 within an individual genotype. h BM cellularity, (i) granulocytes
and macrophages, (j) erythroid cells, (k) percentages of B cell precursors within the B220 + IgM- population, (l) stem cell and multipotent progenitor
populations, (m) the numbers of myelo-erythroid progenitors/femur for each genotype. n Spleen and (o) thymus cellularity. p Representative FACS
plots of Sca-1 expression in the lin-c-Kit+ BM fraction. Representative median fluorescence intensity histogram plots of Sca1 and quantitation of Sca1
expression levels. q Intestine length (stomach – caecum) for each genotype at day of euthanasia or day 29 as indicated in (b). Statistical comparison
(except (b, d)) shown only for R26-CreERki/+ Adar1fl/fl vs. R26-CreERki/+ Adar1fl/E861A and R26-CreERki/+ Adar1fl/flIfih1-/- vs. R26-CreERki/+ Adar1fl/E861AIfih1-/-.
Full statistical analysis of all comparisons in Additional file 6: Table S1. Number of animals per group indicated in (b); data are pooled from two separate
experiments. *P < 0.05; **P < 0.01, ***P < 0.001
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most important function is to edit endogenous RNA to
prevent the formation of endogenous MDA5 substrates.
We do not exclude subtle or additional phenotypes in
the Adar1E861A/E861AIfih1-/- mice that were not appreci-
ated in our analysis, as were demonstrated after the broad
phenotypic testing of the Adar2-/-Gria2R/R mice [10].
Additionally, the analysis of the Adar1E861A/E861AIfih1-/-
animals in non-homeostatic settings, such as when sub-
jected to stress or in pathological settings, may identify
essential functions for ADAR1-mediated editing that are
not apparent under the homeostatic conditions assessed
here. A small number of mammalian conserved, posi-
tively selected recoding events have been identified [49].
While ADAR2 can edit many of these sites, particularly
in the brain, it is also highly likely that the requirement
for these may only become apparent in very specific cir-
cumstances. The known conserved ADAR1 dependent
sites in Bclap and the Htr2c transcript were no longer
edited in the Adar1E861A/E861AIfih1-/- animals. Recoding
events mediated by ADAR1 have been demonstrated
to result in altered protein function. An example is the
recoding of a serine-to-glycine in AZIN1 (p.S365G)
[49, 54]. In this instance, the edited form of AZIN1 is
predicted to result in a gain-of-function allele, whereas
our murine models have a loss of ADAR1-mediated
editing and the physiological consequences of this are
likely to be distinct. Overall, the absence of the con-
served ADAR1-mediated recoding events appears well
tolerated, suggesting that these proteins may have
functions in the whole organism that are either mild/
subtle, that their absence is not sufficient to be patho-
genic in isolation, or that these only demonstrate an
essential requirement in specific settings.
The nexus between ADAR1 and the innate immune
system, centered on the MDA5-MAVS axis, has solidi-
fied due to the work of a number of groups, including
our own [17, 26]. However, the differences between the
Adar1E861A/E861AIfih1-/- animals reported here and the
various Adar1-/- rescued mice are intriguing [17]. Man-
nion et al. reported survival of the Adar1-/-Mavs-/- ani-
mals until the day of birth and that there was normal
histology of internal organs of an Adar1-/-Mavs-/- pup
at this time [26]. Pestal et al. also identified that the
vast majority (>90–95%) of both Adar1-/-Mavs-/- and
Adar1-/-Ifih1-/- pups died by two days after birth. A very
small number of the Adar1-/-Mavs-/- pups were identi-
fied that survived for 13–20 days. These rare Adar1-/-
Mavs-/- survivors had defects in kidney patterning,
small intestines, lymph nodes, and B lymphopoiesis
[17]. The Adar1E861A/E861AIfih1-/- animals do not have
these phenotypes, nor is an absence of B cells apparent
in the cohort of Adar1-/-Ifih1-/- pups we assessed on
the day of birth (Fig. 7a, b). The simplest interpretation
of this is that editing-independent functions of ADAR1
have essential functions, specifically in early post-natal
development. The phenotypes reported for the rescued
Adar1-/- were on a Mavs-/- background, which may be
an important contributing factor to the differences
compared to the Adar1E861A/E861AIfih1-/-. The genetic
rescue of the Adar1-/- achieved by loss of MDA5 was
qualitatively better than MAVS deficiency at the day of
birth [17]. A possible explanation may be that there is a
difference between the cellular consequences of being
Mavs-/- and Ifih1-/-. In Adar1-/-Mavs-/- and Adar1p150-/-
Mavs-/- cells, unedited endogenous dsRNA – the pre-
sumptive candidate immunogenic substrate – are
formed and can be sensed by MDA5. The loss of MAVS
prevents downstream signaling, but sensing and fila-
ment formation by MDA5 remains intact. While the
consequences of MDA5 filament formation in the ab-
sence of signaling is unknown, it is possible based on
the rescue of the Adar1E861A/E861AIfih1-/- animals and
cells that these may in part contribute to the pheno-
types observed. Supporting this, in a cell-based assay of
MDA5 function, 5–10% of signaling activity remained
in the absence of MAVS [58].
To directly assess the contribution of editing-
dependent and editing-independent function of ADAR1
under identical conditions, we assessed pups at the day
of birth and used an adult somatic deletion model that
leaves animals acutely as either Adar1-null (Adar1fl/fl) or
editing deficient (Adar1fl/E861A). The pups assessed on
the day of birth were grossly normal, had normal B cell
frequency in the spleen, and no evidence of activated
ISGs, indicating that an absence of B cells is not an
MDA5-independent function of ADAR1 at the age
assessed but may be a phenotype restricted to those rare
animals that survived 10–20 days after birth [17]. How
these rare Adar1-/-Mavs-/- animals adapted and survived
is unclear. ADAR1p150 appears to have a more specific
function in B-cell homeostasis than ADAR1p110 based
on the analysis of Adar1p150-/-Mavs-/-, which would not
be appreciable in the assays we have completed where
both ADAR1 isoforms are either null or editing deficient
[17]. In the somatic deletion model that we have applied,
there was no/little difference across nearly all cell pop-
ulations enumerated between the being ADAR1 null
and editing-deficient on either an MDA5 WT and null
background. This demonstrated that the Adar1-null
animals were no worse off than animals expressing only
an editing-deficient protein. Second, the phenotypes of
ADAR1 deficiency or of editing loss were comparably
rescued by MDA5 deletion. The somatic deletion of
Adar1 on a Mavs-/- background resulted in disrupted
intestinal homeostasis five days after tamoxifen treat-
ment [17], with the caveat that the Adar1+/+Mavs-/-
control was not described. This was not observed in
the experiments that we completed using the adult
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deletion model on an Ifih1-/- background; however, these
experiments have several important differences in-
cluding Cre strain used and route of tamoxifen admin-
istration that limit direct comparison.
While acknowledging there may be editing-
independent functions of ADAR1 that are only apparent
in early postnatal development, we favor an alternative
interpretation. We hypothesize a critically sensitive time
point in early post-natal development where unedited
dsRNA loads reach a high enough level, akin to the
threshold model proposed for DNA sensing [59], that
development cannot proceed and where having an
ADAR1 protein, even editing-deficient, that can bind
RNA is sufficient to “sequester” the dsRNA, can block/
reduce signaling to a tolerated level. Whether expression
of an editing-deficient cytosolic isoform of ADAR1
would elicit the same effect requires testing. If it were
to reduce innate immune signaling in the absence of
editing, it would support the concept as has been ob-
served in C. elegans and in murine embryonic fibro-
blasts (MEFs) [26, 60]. The subtle innate immune
activation, at least on a transcriptional level in the
Adar1E861A/E861AIfih1-/- tissues, alludes to alternative
minor pathways able to induce the production of ISGs
independent of MDA5 (Fig. 2a). Very recently it was re-
ported that Ribonuclease L deficiency could rescue cell
death associated with deletion of ADAR1 in a human
cell line model [61]. The murine genetic data and res-
cue indicate that such a mechanism does not get acti-
vated in the Adar1E861A/E861AIfih1-/- animals, consistent
with the concept that having a protein capable of binding
RNA, even if incapable of editing, is advantageous com-
pared to being completely deficient for ADAR1.
The present data demonstrate that once MDA5 is neu-
tralized, there are no essential ADAR1-mediated editing
events required for mammalian development and adult
homeostasis. We do not find evidence for an analogous
essential protein recoding event(s) mediated by ADAR1
to that of Gria2 for ADAR2. Moreover, A-to-I editing by
ADAR1 of a variety of substrates, including the editing
of miRNAs and their target sequences, outside of modi-
fying the potential for these to interact with MDA5, is
neither essential nor required for normal mammalian
homeostasis. The parallels between the ADAR1 null and
editing-deficient models suggest that editing independent
roles of ADAR1 are not significant contributors to the in
vivo phenotypes associated with loss of ADAR1. As the
transcriptional response and cellular consequences of loss
of ADAR1 are conserved across mammals, these data have
implications for humans with ADAR1 mutations, particu-
larly those with AGS [17, 21, 52]. Our data demonstrate
that if MDA5 activity/expression can be prevented or re-
duced, even in the context of a completely editing-
deficient ADAR1 protein, this is sufficient to result in
largely normal development with limited consequences on
long-term organ and tissue homeostasis.
Conclusions
These analyses demonstrate that the lifetime absence of
ADAR1-editing is well tolerated, once MDA5 is inacti-
vated. We conclude that protein recoding arising from
ADAR1-mediated editing, unlike ADAR2, is not essen-
tial for organismal homeostasis. The comparison of both
germline and acute somatic deficient Adar1-/- and
Adar1E861A animals, on either a WT and MDA5-
deficient background, did not identify distinct differences
between being ADAR1 protein-deficient and having only
the expression of an editing dead protein. The pheno-
types associated with loss of ADAR1 are the result of
RNA editing and MDA5-dependent functions. A-to-I
editing by ADAR1 of a variety of substrates, including
the editing of miRNAs and their target sequences, out-
side of modifying the potential for these to interact with
MDA5, is neither essential nor required for normal
mammalian homeostasis.
Methods
Animals
All animal experiments were approved by the AEC
(AEC#030/14 and AEC#031/15; St. Vincent’s Hospital,
Melbourne). AdarE861A/+ (Adar1E861A/+; MGI allele:
Adartm1.1Xen; MGI:5805648), Ifih1-/- (Ifih1tm1.1Cln), Adar-/-
(Adar1-/-; MGI allele: Adartm2Phs; MGI:3029862), Adarfl/fl
(Adar1fl/fl; MGI allele: Adartm1.1Phs; MGI:3828307), and
Rosa26-CreERT2 (Gt(ROSA)26Sortm1(cre/ERT2)Tyj) mice
were on a backcrossed C57BL/6 background as previ-
ously described [14, 18, 19, 62, 63]. For day of birth ana-
lysis, females were plug mated and pups collected before
midday on the day of birth. For acute somatic deletion
model, all animals were aged ≥ 8 weeks at tamoxifen
initiation; tamoxifen-containing food was prepared at
400 mg/kg tamoxifen citrate (Sigma) in standard mouse
chow (Specialty Feeds, WA, Australia).
Histology
Four (two males, two females) 12-week-old Adar1E861A/+
Ifih1-/- and Adar1E861A/E861AIfih1-/- littermates were used
for histopathology examination. Tissue collection and
histology was performed by the Australian Phenomics
Network Histopathology and Organ Pathology Core,
University of Melbourne. One male and one female
Adar1E861A/+Ifih1-/- were genotype identified to the pa-
thologists as “controls,” the remaining samples were
genotype blinded. Sections were assessed by independent
pathologists. The full pathology report is available in
Additional file 3: Dataset S1.
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Flow cytometry analysis and fluorescent activated
cell sorting
Peripheral blood was analyzed on a hematological
analyzer (Sysmex KX-21 N, Roche Diagnostics). Single-
cell BM, spleen, and thymus suspensions were prepared
by passing through a 23-G needle (BM) or crushing
through a 40-μm cell strainer (spleen/thymus) [64].
Antibodies against murine Ter119, CD71, B220, IgM,
CD11b/Mac1, Gr1, F4/80, CD43, CD19, CD4, CD8,
CD44, Sca-1, c-Kit, CD34, FLT3, FcγR (CD16/32),
CD41, CD105, and CD150 were either biotinylated or
conjugated with FITC; phycoerythrin, phycoerythrin-Cy5,
peridinin chlorophyll protein-Cy5.5, phycoerythrin-Cy7,
allophycocyanin, or allophycocyanin eFluor780 were all
obtained from eBioscience. CD105 and CD150 were
from BioLegend. Biotinylated antibodies were detected
with streptavidin conjugated with Brilliant Violet-605
(Biolegend). Cells were analyzed on a BD LSRIIFortessa
(BD Biosciences). Results were analyzed with FlowJo
software Version 10.0 (Treestar).
For serum cytokine/chemokine expression analysis,
serum was isolated from peripheral blood and assessed
using a custom bead-based immunoassay (LEGENDPlex,
BioLegend) measuring murine IFNγ IFNβ, IL-10, TNFα,
CXCL10, CXCL1, CCL2, and CCL11. Serum from age-
and sex-matched WT C57B6/J mice from the same
rooms of the BioResources Facility were run in parallel.
Samples were assessed on BD LSRIIFortessa (BD Biosci-
ences). Results were analyzed with LEGENDPlex software
version 7.0 (Biolegend). As a control, tissue culture media
was isolated from immortalized myeloid progenitor cells
generated from Rosa26-CreERT2 Adar1E861A/fl cell lines
that were treated with 200 nM tamoxifen for four days to
delete the WT Adar1 allele. These cells were immortalized
with HoxA9 and selected for proliferation in GM-CSF
conditioned media as described [44].
Micro-computed tomography analysis of bone
parameters (microCT)
Ex vivo microCT was performed on tibiae using the Sky-
Scan1076 system (Bruker-microCT, Kontich, Belgium)
essentially as previously described [47]. Male and female
12-week-old tibia were isolated, fixed overnight in 2%
paraformaldehyde, and then stored in 70% ethanol until
imaged. Images were acquired using the following set-
tings: pixel size = 9 μm, aluminum filter = 0.5 mm, volt-
age = 45 kV, current = 220 μA, rotation = 0.7°, and frame
averaging = 1. Images were reconstructed and analyzed
with SkyScan software programs NRecon (version
1.6.3.3), DataViewer (version 1.4.4), CT Analyser (CTan,
version 1.12.0.0), and CTVox (version 2.2.0). The tra-
becular analysis region of interest (ROI) was determined
by identifying the start of the mineralized zone of the
proximal growth plate and calculating 3% of the total
tibial length towards the tibial mid-shaft, where we then
analyzed an ROI of 13.5% of the total tibial length. Ana-
lysis of trabecular bone structure was completed using
adaptive thresholding (mean of min and max values) in
CTan with threshold set at 45–255 for trabecular bone.
Cortical analyses were performed at 40% of the total
tibial length distal from the mineralized zone of the
proximal growth plate and extending for 13.5% of the
total tibial length; the threshold values for cortical bone
were set to 79–255 and global thresholding algorithm
was used. The three-dimensional visualization of tra-
becular and cortical bone was performed with CTVox,
where volume-rendered images were pseudo-colored
based on grayscale (pixel) intensity that is reflective of
bone mineralization.
qRT-PCR
Mouse tissues from three independent biological repli-
cates from age-matched and sex-matched C57BL/6,
Adar1+/+Ifih1-/-, and Adar1E861A/E861AIfih1-/- mice were
homogenized in Trisure reagent using IKA T10 basic S5
Ultra-turrax Disperser. Brain tissue was isolated from
the pups collected at the day of birth and snap-frozen,
then homogenized in Trisure reagent using IKA T10
basic S5 Ultra-turrax Disperser. RNA was extracted
using Direct-Zol columns (Zymo Research) as per man-
ufacturer’s instructions. Complementary DNA (cDNA)
was synthesized using Tetro cDNA synthesis kit (Bio-
line). Real-time PCR was done in duplicate with Brilliant
II SYBR Green QPCR Master Mix (Agilent Technolo-
gies) and primers from IDT (Additional file 3: Table S2).
All primers were optimized to have equal efficiency (100
+/-10%) before use. Ppia was used as a reference gene for
relative quantification using the ΔCt method. RNA was
obtained from fetal brain from E12.5 Adar1E861A/E861A
embryos and processed as described above [19].
Microfluidics-based multiplex PCR and deep sequencing
(mmPCR-seq) identification of A-to-I editing sites
Whole brain, kidney, spleen, thymus, BM, heart, and small
intestines from three independent biological replicates
from Adar1+/+Ifih1-/- and Adar1E861A/E861AIfih1-/- were
used for mmPCR-seq. Following tissue homogenization,
RNA was isolated using TRIsure reagent (Bioline) and
Direct-Zol columns (Zymo Research). cDNA was syn-
thesized using iScript Advanced Kit (BioRad) using 1.2–
7.5 μg RNA per tissue. A total of 200 ng of cDNA was
used for mmPCR-seq targeting 557 loci containing
11,103 known A-to-I editing sites [48]. A-to-I editing
frequency was assessed using the criteria: minimum
coverage > 100 (in 2/3) of WT (Adar1+/+Ifih1-/-) and de-
ficient (Adar1E861A/E861AIfih1-/-). For a given site, where
a replicate had ≤ 100 reads that measurement is regarded
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as a missing value. All editing sites with editing ≤ 0.01
were removed, leaving 413–808 sites per tissue. Sites
were ADAR1-specific targets if the editing level mea-
surements between the WT (Adar1+/+Ifih1-/-) replicates
and the editing-deficient (Adar1E861A/E861AIfih1-/-) repli-
cates were significantly different (P < 0.1, ANOVA) and
the average editing levels between WT and editing-
deficient samples differed by at least 5% [48].
RNA-seq samples: adult brain
Total RNA was isolated from the whole brain from 12-
week-old male Adar1+/+Ifih1-/- and Adar1E861A/E861AIfih1-/-
mice (n = 3/genotype). Sequins were included before ribo-
some depletion [65]. Post ribosome-depleted RNA was
purified and subjected to indexing and library preparation
using the Kapa Stranded RNA-seq Library Preparation Kit
(Kapa Biosystems) and sequenced using the Illumina Next-
Seq500 with 75-bp paired-end reads by the Ramaciotti
Centre for Genomics (UNSW, Australia).
RNA-seq samples: fetal brain
Total RNA was isolated from the whole brain from E12.5
old male Adar1+/+Ifih1-/- and Adar1E861A/E861AIfih1-/- mice
(n = 3/genotype). RNA was purified and subjected to
indexing and library preparation using the Illumina TruSeq
RNA Sample Prep Kit v2. The libraries were sequenced
using the Illumina HiSeq2000 with 100-bp paired-end
reads by the Ramaciotti Centre for Genomics (UNSW,
Australia).
RNA-seq analysis
RNA-seq reads from adult brain were aligned to the
MM9/NCBIM37 reference genome with STAR [66]
and gene counts were determined using “–quantMode
GeneCounts.” Differential gene expression analysis was
performed using the Degust analysis tool (http://victorian-
bioinformatics-consortium.github.io/degust/); briefly, genes
were only considered with a CPM of ≥ 2 in 3/3 replicates
of either the Adar1E861A/E861AIfih1-/- or Adar1+/+Ifih1-/-
(13,891 genes). Normalized read counts (moderated
log counts per million) and differential expression
were generated using edgeR [67] and genes were
considered differentially expressed if FDR < 0.05 (124
genes: 81 up, 43 down). Adding a magnitude require-
ment to the fold change of abs(log2FC) > 1 resulted in
29 genes (24 up, 5 down).
RNA-seq reads from fetal brain were aligned to the
MM9/NCBIM37 reference genome with STAR [66] and
gene counts were determined using “–quantMode Gene-
Counts.” Differential gene expression analysis was per-
formed using the Degust analysis tool (http://victorian-
bioinformatics-consortium.github.io/degust/); briefly, genes
were only considered with a CPM of ≥ 2 in 3/3 replicates
of either the Adar1E861A/E861AIfih1-/- or Adar1+/+Ifih1-/-
(13,786 genes). Normalized read counts (moderated log
counts per million) and differential expression were
generated using edgeR [67] and genes were considered
differentially expressed if FDR < 0.05 (808 genes: 745
up, 57 down). Adding a magnitude requirement to the
fold change of abs(log2FC) > 1 resulted in 303 genes
(294 up, 9 down).
GO term enrichment of genes using PANTHER
PANTHER Overrepresentation Test [68] (release 20160715):
PANTHER version 11.1 was used to perform statistical
testing on sets of differential genes using allMus musculus
genes as the reference list against GO biological processes,
using Bonferroni multiple testing correction.
QuSAGE gene set testing
Quantitative Set Analysis for Gene Expression (QuSAGE)
was performed as described [69] against the MSigDB
collection “C2:curated gene sets” (c2.cgp.v4.0).
Datasets
All datasets related to this work are deposited in GEO.
RNA-seq accessions:
GSE94387 (adult brain)
GSE94388 (fetal brain)
GSE94386 (mmPCR-seq: BM, spleen, thymus, liver,
brain, kidney, small intestine, and heart)
Statistical analysis
For biological experiments, the significance of results
was analyzed using the one-way or two-way ANOVA
with multiple comparison corrections unless otherwise
stated, P < 0.05 was considered significant. All data are
presented as mean ± SEM.
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Additional file 1: Movie S1 Video of 12-week-old male mice.
(MOV 11186 kb)
Additional file 2: Movie S2 Video of 12-week-old female mice.
(MOV 6740 kb)
Additional file 3: Dataset S1 Full histopathology report (related to Fig. 4),
Figure S1 (related to Fig. 4) 12-week-old female mouse bone parameters
(full legend with figure). Figure S2 (related to Fig. 7) Spleen and thymus
data from R26-CreER Adar1fl/flIfih1-/- and R26-CreER Adar1fl/E861AIfih1-/- and
control animals (full legend with figure). Table S2 qPCR primers used
in this study. (PDF 882 kb)
Additional file 4: Dataset S2 RNA-seq data (related to Fig. 5).
(XLSX 9999 kb)
Additional file 5: Dataset S3 mmPCR-seq data (related to Fig. 6).
(XLSX 1061 kb)
Additional file 6: Table S1 Full statistical comparison of data in Fig. 7.
(XLSX 120 kb)
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